Related Experiment Video
Updated: Jun 19, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
RHD deletion in a patient with chronic myeloid leukemia
A Murdock1, D Assip, K Hue-Roye
1Good Samaritan Hospital Medical Center, West Islip, NY, USA.
Insights
A patient with chronic myeloid leukemia experienced a change in RhD antigen status from positive to negative. Molecular analysis revealed a deleted RHD gene in their white blood cells, explaining the altered D antigen expression.
Area of Science:
- Genetics
- Hematology
- Immunology
Background:
- Anomalous RhD antigen expression is occasionally seen in myeloproliferative disorders.
- The RH gene's location was initially suggested by this phenomenon.
Observation:
- An 82-year-old Caucasian patient with chronic myeloid leukemia transitioned from RhD-positive to RhD-negative status.
- This change in red blood cell (RBC) typing occurred over several months in 2006.
Findings:
- PCR-based assays on the patient's white blood cell (WBC) DNA showed a deletion of RHD-specific exons.
- A hybrid Rhesus box was detected, indicating a deleted RHD gene.
- RHCE gene amplification was normal, predicting a C-E-c+e+ phenotype.
Implications:
- The study identifies a deleted RHD gene as the molecular mechanism for the RhD antigen status change.
- This finding contributes to understanding RhD antigen variability in hematological malignancies.
- Provides insights into the genetic basis of RhD antigen expression in disease states.
Abstract:
Anomalous expression of the Rh antigen, D, has occasionally been observed in patients with certain myeloproliferative disorders. Indeed, this phenomenon led to the tentative assignment of RH to the short arm of chromosome 1. PCR-based analyses were performed on DNA from an 82-year-old D+ Caucasian patient with chronic myeloid leukemia after her RBCs became D-. For nearly 7 years, the patient's RBCs typed as strongly D+, but in March 2006, they typed weakly D+ and in August 2006 typed D- by both direct hemagglutination and the IAT. The D- typing persisted until the patient's death in September 2006. To study the underlying cause of the change in D type, PCR-based assays were performed on DNA extracted from peripheral WBCs from the patient's sample collected in August 2006. No amplification was obtained using primers designed to amplify RHD exons 5, 8, or 10, and intron 4. Very weak amplification was obtained using primers designed to amplify RHD exons 3, 4, or 7. Two assays that detect the hybrid Rhesus box showed deletion of RHD. Amplification of RHCE in the patient's DNA was as efficient as that of control samples, and multiplex and PCR-RFLP assays predicted her RBCs would be C-E-c+e+. Based on finding a hybrid Rhesus box and absence of D-specific exons, we conclude that DNA from the patient's WBCs carries a deleted RHD. This explains the molecular mechanism underlying the change from D+ to D-.
More Related Videos
06:39Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018